Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.59 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25858 | 1.00 | CACNA2D1 (0.59) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3245952 | 1.00 | CACNA2D1 (0.59) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4387074 | 1.00 | CACNA2D1 (0.59) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4383738 | 1.00 | CACNA2D1 (0.59) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1814331 | 1.00 | CACNA2D1 (0.59) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Hydrochloric Acid SCHEMBL3833106 | 0.98 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Hydrochloric Acid SCHEMBL3116514 | 0.98 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Hydrochloric Acid SCHEMBL3833112 | 0.98 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3119131 | 0.95 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL26083 | 0.95 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | claimed |
| EP-2172197-A1 | Octanoic acid derivative to treat fibromyalgia and other pains | Warner-Lambert Company LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | PFIZER INC. | 2009-12-03 | — | — | US | disclosed |
| EP-1192125-B9 | MONO-SUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER LAMBERT CO (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | PFIZER INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | PFIZER INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | PFIZER INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2017259-A2 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | Pfizer Products Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1192125-B1 | MONO-SUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER LAMBERT CO (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1973867-A1 | PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Pfizer Products Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7164034-B2 | Alpha2delta ligands for fibromyalgia and other disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-7138542-B2 | Method of treating tinnitus | WARNER LAMBERT COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060100281-A1 | Method of treating tinnitus | DOOLEY DAVID J | 2006-05-11 | — | — | US | disclosed |
| US-7026505-B2 | Method of treating tinnitus | WARNER-LAMBERT COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | disclosed |
| US-6642398-B2 | Improving drug qualities such as bioavailability and stability | WARNER-LAMBERT COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | BELLIOTTI THOMAS RICHARD (US) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | CACNA2D1 1075/4885CACNB3 529/4885CACNA1C 265/4885 |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | CACNA2D1 3541/4885CACNB3 1477/4885CACNA1C 2966/4885 |
| US-20060100281-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRB2 | CACNA2D1 1282/4885CACNB3 944/4885CACNA1C 678/4885 |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | OPRD1, HCRTR2, OPRL1 | CACNA2D1 948/4885CACNB3 867/4885CACNA1C 640/4885 |
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | SCN2A, CACNG2, SCN1A | CACNA2D1 26/4885CACNB3 56/4885CACNA1C 29/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CACNA2D1 2778/4885CACNB3 1948/4885CACNA1C 1996/4885 |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | GABRB1, GABRA1, GABRB3 | CACNA2D1 484/4885CACNB3 586/4885CACNA1C 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.